Literature DB >> 32414210

Erratum: Benelli, R., et al. Aspartate-β-Hydroxylase: A Promising Target to Limit the Local Invasiveness of Colorectal Cancer. Cancers 2020, 12, 971.

Roberto Benelli1, Delfina Costa1, Luca Mastracci2,3, Federica Grillo2,3, Mark Jon Olsen4, Paola Barboro5, Alessandro Poggi1, Nicoletta Ferrari1.   

Abstract

The authors wish to make the following corrections to this paper [...].

Entities:  

Year:  2020        PMID： 32414210      PMCID： PMC7281291          DOI： 10.3390/cancers12051226

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN： 2072-6694            Impact factor:   6.639


The authors wish to make the following corrections to this paper [1]: Please note that Midwestern University signed the technology transfer agreement very recently, this is the reason why we forgot to modify the conflict of interest statement in the last revision of the manuscript. The “Conflicts of Interest” statement should be changed to: Conflicts of Interest: M.J.O. is the CEO of Crenae Therapeutics which has licensed ASPH inhibitor technologies from Midwestern University. The other authors declare no conflict of interest. The authors would like to apologize for any inconvenience caused to the readers by these changes.
  1 in total

1.  Aspartate-β-Hydroxylase: A Promising Target to Limit the Local Invasiveness of Colorectal Cancer.

Authors:  Roberto Benelli; Delfina Costa; Luca Mastracci; Federica Grillo; Mark Jon Olsen; Paola Barboro; Alessandro Poggi; Nicoletta Ferrari
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639
  1 in total
  1 in total

Review 1.  Aspartate β-hydroxylase as a target for cancer therapy.

Authors:  Madiha Kanwal; Michal Smahel; Mark Olsen; Jana Smahelova; Ruth Tachezy
Journal:  J Exp Clin Cancer Res       Date:  2020-08-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.